A Review of Thrombopoietin Receptor Agonists and Subsequent Development of Thrombosis: Exploring a Hematologic Paradox. (PubMed, Cureus) - Oct 5, 2026 - "Agents such as romiplostim, eltrombopag, avatrombopag, and lusutrombopag act in different ways to stimulate megakaryopoiesis. These agents are used in both adult and pediatric populations, primarily in chronic immune thrombocytopenia, severe aplastic anemia, and myelodysplastic syndrome, as well as pre-procedural in patients with chronic liver disease. This literature review summarizes the current TPO-RAs and aims to evaluate the risk of thrombus formation. Past studies have been inconsistent in significantly associating thrombotic events with higher platelet counts, medication doses, or drug mechanisms of action. The pathophysiology appears to be multifactorial, with some theories suggesting risk from increased thrombopoiesis with potential alterations in platelet activity or an already prothrombotic patient state due to underlying disease or individual predisposing factors. Risks such as prior thrombus..."
Journal • Review • Aplastic Anemia • Cardiovascular • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Hepatology • Immune Thrombocytopenic Purpura • Myelodysplastic Syndrome • Oncology • Pediatrics • Thrombocytopenia • Thrombocytopenic Purpura • Thrombocytosis • Thrombosis
|
|
Arun Nair; Gillian Graifman; Rajesh Varma C P; Ranya Parekh
|